New research has found that a drug used to treat severe forms of acne reduces the availability of the chemical serotonin, low levels of which have been linked to aggression and clinical depression.
In a study published in the journal Experimental Biology and Medicine, scientists reveal a potential mechanism that might link the drug Roaccutane (Accutane in the US) to reported cases of depression in some patients taking the medication.
The researchers had previously reported that the drug caused depressive behaviour in mice but, until now, the mechanism by which this might happen was unknown.
Using cells cultured in a laboratory, scientists from the University of Bath (UK) and University of Texas at Austin (USA) were able to monitor the effect of the drug on the chemistry of the cells that produce serotonin.
They found that the cells significantly increased production of proteins and cell metabolites that are known to reduce the availability of serotonin.
This, says scientists, could disrupt the process by which serotonin relays signals between neurons in the brain and may be the cause of depression-related behaviour.
“Serotonin is an important chemical that relays signals from nerve cells to other cells in the body,” said Dr Sarah Bailey from the Department of Pharmacy & Pharmacology at the University of Bath.
“In the brain it is thought to play an important role in the regulation of a range of behaviours, such as aggression, anger and sleep.
“Low levels of serotonin have been linked to depression, as well as bipolar and anxiety disorders.
“Many medications aimed at treating depression seek to increase levels of serotonin to help overcome these problems.
“Our findings suggest that Roaccutane might disrupt the way serotonin is produced and made available to the cells.
“This could result in problems associated with low levels of serotonin, which might include depression.
“We are currently looking into this mechanism in more detail.”
Source: University of Bath
Related stories:
Learned safety cheers depressed mice: An animal model of behavioral intervention for depression
A new animal model has provided insight into the cellular and molecular mechanisms associated with behavioral therapy for depression. The study, published by Cell Press in the October 9th issue of
Neuron, may provide a good model system for testing cellular and molecular interactions between antidepressive medications and behavioral treatments for depression.
Learning how not to be afraid
Why do some people have the ability to remain calm and relaxed even in the most stressful situations? New experiments in mice by Howard Hughes Medical Institute (HHMI) researchers are providing insight into how the brain changes when the animals learn to feel safe and secure in situations that would normally make them anxious.
Biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
Biophysicists at the University of Pennsylvania have used 3,200 computer processors and long-established data on cholesterol's role in the function of proteins to clarify the mysterious interaction between cholesterol and neurotransmitter receptors. The results provide a new model of behavior for the nicotinic acetylcholine receptor, a well studied protein involved in inflammation, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, the effect of general anesthetics and addiction to alcohol, nicotine and cocaine.
PET scans help identify mechanism underlying seasonal mood changes
Brain scans taken at different times of year suggest that the actions of the serotonin transporter—involved in regulating the mood-altering neurotransmitter serotonin—vary by season, according to a report in the September issue of
Archives of General Psychiatry. These fluctuations may potentially explain seasonal affective disorder and related mood changes.
Protein on 'speed' linked to ADHD
A genetic change in the dopamine transporter – one of the brain's dopamine-handling proteins – makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in
The Journal of Neuroscience.
Researchers clarify function of glucose transport molecule
Researchers at the David Geffen School of Medicine at UCLA have solved the structure of a class of proteins known as sodium glucose co-transporters (SGLTs), which pump glucose into cells. These transport proteins are used in the treatment of chronic diarrhea via oral rehydration therapy, saving the lives of millions of children each year. The solution of the SGLT structure will accelerate development of new drugs designed to treat patients with diabetes and cancer.
Serotonin may affect our sense of fairness, scientists report
The neurotransmitter serotonin, which acts as a chemical messenger between nerve cells, plays a critical role in regulating emotions such as aggression during social decision-making, new research by scientists at England's University of Cambridge and UCLA suggests. Their findings appear June 6 in the peer-reviewed journal
Science.
New research explores role of serotonin in decision-making behaviour
New research by scientists at the University of Cambridge suggests that the neurotransmitter serotonin, which acts as a chemical messenger between nerve cells, plays a critical role in regulating emotions such as aggression during social decision-making.